Bill Kaelin

Bill Kaelin’s distinguished research career has focused on the proteins encoded by tumor suppressor genes and how mutations in those genes cause cancer. His work on the VHL protein delivered new insights into how cells respond to changes in oxygen levels – and motivated the successful clinical testing of VEGF inhibitors, which are now approved to treat kidney cancer. A professor at the Dana-Farber Cancer Institute and Harvard Medical School, Bill brings deep expertise in the regulation of oncoproteins to Cedilla. He also brings a unique cell-based assay that quickly screens cells to find upstream regulators that control the stability of proteins. Bill has won many top scientific honors, including the ASCO Science of Oncology Award, the Canada Gairdner International Award and the Albert Lasker Award for Basic Medical Research. He sits on the editorial board of numerous journals, including Cancer Cell, and has served on the National Cancer Institute’s Board of Scientific Advisors. Bill received his M.D. from Duke University